SK7012003A3 - Fibroblast growth factors - Google Patents

Fibroblast growth factors Download PDF

Info

Publication number
SK7012003A3
SK7012003A3 SK701-2003A SK7012003A SK7012003A3 SK 7012003 A3 SK7012003 A3 SK 7012003A3 SK 7012003 A SK7012003 A SK 7012003A SK 7012003 A3 SK7012003 A3 SK 7012003A3
Authority
SK
Slovakia
Prior art keywords
fgf
polypeptide
composition
amino acid
leu
Prior art date
Application number
SK701-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Peter W Bringmann
Daryl Faulds
Branislava Mitrovic
Subha Srinivasan
James Onuffer
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of SK7012003A3 publication Critical patent/SK7012003A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK701-2003A 2000-12-08 2001-12-10 Fibroblast growth factors SK7012003A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25183700P 2000-12-08 2000-12-08
US10/005,646 US20020151496A1 (en) 2000-12-08 2001-12-07 Novel fibroblast growth factors
PCT/US2001/047350 WO2002046424A2 (en) 2000-12-08 2001-12-10 Fibroblast growth factors

Publications (1)

Publication Number Publication Date
SK7012003A3 true SK7012003A3 (en) 2004-04-06

Family

ID=26674594

Family Applications (1)

Application Number Title Priority Date Filing Date
SK701-2003A SK7012003A3 (en) 2000-12-08 2001-12-10 Fibroblast growth factors

Country Status (21)

Country Link
US (2) US20020151496A1 (cg-RX-API-DMAC7.html)
EP (1) EP1389237A2 (cg-RX-API-DMAC7.html)
JP (1) JP2005506275A (cg-RX-API-DMAC7.html)
KR (1) KR20040052442A (cg-RX-API-DMAC7.html)
CN (1) CN1518597A (cg-RX-API-DMAC7.html)
AU (1) AU2603402A (cg-RX-API-DMAC7.html)
BG (1) BG107888A (cg-RX-API-DMAC7.html)
BR (1) BR0116507A (cg-RX-API-DMAC7.html)
CA (1) CA2431374A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20031570A3 (cg-RX-API-DMAC7.html)
EE (1) EE200300269A (cg-RX-API-DMAC7.html)
HU (1) HUP0400657A1 (cg-RX-API-DMAC7.html)
IL (1) IL156259A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03005142A (cg-RX-API-DMAC7.html)
NO (1) NO20032573L (cg-RX-API-DMAC7.html)
PL (1) PL366158A1 (cg-RX-API-DMAC7.html)
RU (1) RU2329058C2 (cg-RX-API-DMAC7.html)
SI (1) SI21372A (cg-RX-API-DMAC7.html)
SK (1) SK7012003A3 (cg-RX-API-DMAC7.html)
WO (1) WO2002046424A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200305236B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
WO2003059270A2 (en) * 2002-01-15 2003-07-24 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
EP1608411B1 (en) * 2003-04-01 2010-09-29 United States Government as represented by the Department of Veteran's Affaires Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure.
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
LT2726511T (lt) 2011-07-01 2019-11-11 Ngm Biopharmaceuticals Inc Kompozicijos, panaudojimai ir būdai, skirti metabolinių sutrikimų ir ligų gydymui
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
AU2013352363B2 (en) 2012-11-28 2018-04-12 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
AU2013370404B2 (en) 2012-12-27 2017-11-02 Ngm Biopharmaceuticals, Inc. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX377380B (es) 2013-10-28 2025-03-10 Ngm Biopharmaceuticals Inc Modelos de cáncer y métodos asociados.
SI3097122T1 (sl) 2014-01-24 2020-07-31 Ngm Biopharmaceuticals, Inc. Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
UA123763C2 (uk) 2014-10-23 2021-06-02 Енджіем Байофармасьютикалз, Інк. Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
WO2000060085A1 (en) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
JP2003512841A (ja) * 1999-10-22 2003-04-08 カイロン コーポレイション ヒトおよびラットfgf−20遺伝子および遺伝子発現産物
JP2003516731A (ja) * 1999-11-18 2003-05-20 カイロン コーポレイション ヒトfgf−21遺伝子および遺伝子発現産物
AU2001262934A1 (en) * 2000-06-01 2001-12-11 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
WO2002002625A2 (en) * 2000-07-03 2002-01-10 Curagen Corporation Novel fibroblast growth factors and nucleic acids encoding same

Also Published As

Publication number Publication date
JP2005506275A (ja) 2005-03-03
CA2431374A1 (en) 2002-06-13
HUP0400657A1 (en) 2006-04-28
US20080057076A1 (en) 2008-03-06
ZA200305236B (en) 2005-06-29
SI21372A (sl) 2004-06-30
EP1389237A2 (en) 2004-02-18
RU2003119657A (ru) 2005-02-27
AU2002226034A2 (en) 2002-06-18
IL156259A0 (en) 2004-01-04
BR0116507A (pt) 2004-01-06
NO20032573D0 (no) 2003-06-06
RU2329058C2 (ru) 2008-07-20
CN1518597A (zh) 2004-08-04
CZ20031570A3 (cs) 2004-01-14
KR20040052442A (ko) 2004-06-23
BG107888A (bg) 2004-08-31
AU2603402A (en) 2002-06-18
US20020151496A1 (en) 2002-10-17
NO20032573L (no) 2003-07-22
WO2002046424A3 (en) 2003-11-27
EE200300269A (et) 2003-10-15
PL366158A1 (en) 2005-01-24
MXPA03005142A (es) 2004-10-15
WO2002046424A2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
US20080057076A1 (en) Novel fibroblast growth factors
KR100924183B1 (ko) 신규 섬유아세포 성장 인자 (fgf23) 및 그의 이용 방법
KR100728405B1 (ko) Nogo 유전자의 뉴클레오티드와 단백질 서열 및 이들에기초한 방법
AU769166B2 (en) Fizz proteins
JP2002513037A5 (cg-RX-API-DMAC7.html)
WO1998007736A9 (en) Don-1 gene and polypeptides and uses therefor
AU4154097A (en) Don-1 gene and polypeptides and uses therefor
AU2002226034B2 (en) Fibroblast growth factors
US5750365A (en) Isolated nucleic acid encoding a newt acidic fibroblast growth factor (AFGF)
JP2004504042A (ja) グリコシル化vegf−b及び可溶性vegf−bの量を増加させるための方法
AU2002226034A1 (en) Fibroblast growth factors
AU2007203341A1 (en) Fibroblast growth factors
HK1068648A (en) Novel fibroblast growth factors
US20020127594A1 (en) Don-1 gene and polypeptides and uses therefor
US6537554B1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
CA2335326A1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US20030104573A1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
HK1140493A (en) Nucleotide and protein sequences of nogo genes and methods based thereon

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure